# US 2020/0368364 A1 · Cysteine peptide-enabled antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0368364 A1
- Document ID: US20200368364A1
- Status: Published application
- Kind: A1
- Application number: 16/467,450
- Filed: 2017-12-06
- Published: 2020-11-26
- Earliest claimed: 2016-12-06
- Assignees: City of Hope
- Applicants: City of Hope
- Inventors: John C. Williams; Krzysztof Bzymek; Yuelong Ma; David Horne; Jeremy King
- Web page: https://patentgrep.com/patent/US20200368364A1

## CPC

- C07K 7/06: having 5 to 11 amino acids
- A61K 47/68031: {the drug being an auristatin}
- A61K 47/68033: {the drug being a maytansine}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 16/283: {against Fc-receptors, e.g. CD16, CD32, CD64 (CD23 C07K16/2851)}
- C07K 16/32: against translation products of oncogenes
- C07K 2317/522: CH1 domain
- C07K 2317/55: Fab or Fab'
- C07K 2317/624: Disulfide-stabilized antibody (dsFv)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein are functionalized monoclonal antibodies (mAbs) including antibody fragments covalently linked to a peptide compound through a disulfide linkage. The disulfide linkage is between a cysteine in the Fab region of the antibody or fragment thereof and a thiol moiety of a side chain amino acid of the peptide compound. The covalently formed complexes including provided herein form highly stable and versatile drug delivery and diagnostic compositions.

## Claims

### Claim 1

A covalent complex comprising:
(i) an antigen binding domain comprising:
(1) a central hole enclosed by the heavy chain variable (VH) region, the light chain variable (VL) region, the heavy chain constant (CH1) region and the light chain constant (CL) region of said antigen binding domain between a first cavity and a second cavity; and
(2) a non-CDR peptide binding region comprising:
(a) said first cavity lined by a first set of amino acid residues of the VH, VL, CH1, and CL regions of said antigen binding domain;
(b) said second cavity lined by a second set of amino acid residues of the VH, VL, CH1, and CL regions of said antigen binding domain; and
(c) a hole region enclosing said hole between said first cavity and said second cavity, said hole region lined by a third set of amino acid residues of the VH, VL, CH1, and CL regions of said antigen binding domain;
wherein said non-CDR peptide binding region comprises a first cysteine; and
(ii) a peptide compound comprising a thiol side chain amino acid covalently bound to said antigen binding domain through a disulfide linkage between said first cysteine and said thiol side chain amino acid.

### Claim 2 (depends on 1)

The covalent complex of claim 1, wherein said second set of amino acid residues comprises said first cysteine at a position corresponding to Kabat position 158 of said VH region.

### Claim 3 (depends on 1)

The covalent complex of claim 1, wherein said third set of amino acid residues comprises said first cysteine at a position corresponding to Kabat position 175 of said VH region.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The covalent complex of claim 1, wherein said peptide compound has the formula:
R1—X0-X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-R2 (I)
wherein:
X0 is Ser or null;
X1 is Ser, Cys, Gly, β-alanine, diaminopropionic acid, β-azidoalanine, or null;
X2 is Gln or null;
X3 is Phe, Tyr, β,β′-diphenyl-Ala, His, Asp, 2-bromo-L-phenylalanine, 3-bromo-L-phenylalanine, 4-bromo-L-phenylalanine, Asn, Gln, a modified Phe, a hydratable carbonyl-containing residue, or a boronic acid-containing residue;
X4 is Asp or Asn;
X5 is Leu, β,β′-diphenyl-Ala, Phe, Trp, Tyr, a non-natural analog of phenylalanine, tryptophan, or tyrosine, a hydratable carbonyl-containing residue, or a boronic acid-containing residue;
X6 is said thiol side chain amino acid or serine;
X7 is the thiol side chain amino acid, Thr, or Ser;
X8 is said thiol side chain amino acid, Arg, Ala, or an amino acid comprising a side chain of the formula -L3A-L3B-R3, wherein L3A is a bond, —O—, —S—, —C(O)—, —C(O)O—, —C(O)NH—, —S(O)2NH—, —NH—, —NHC(O)NH—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene or substituted or unsubstituted heteroarylene, L3B is a chemical linker and R3 is a steric hindering chemical moiety;
X9 is the thiol side chain amino acid, Arg or Ala;
X10 is Leu, Gln, Phe, Trp, Tyr; a non-natural analog of phenylalanine, tryptophan, or tyrosine, a hydratable carbonyl-containing residue, or a boronic acid-containing residue;
X11 is the thiol side chain amino acid, Gln, Lys or Arg;
X12 is Ser, Cys, Gly, 7-aminoheptanoic acid, β-alanine, diaminopropionic acid, propargylglycine, isoaspartic acid, or null;
R1 is null, -L10A-L10B-R10, an amino acid peptide sequence optionally substituted with -L10A-L10B-R10;
R2 is null, -L20A-L20B-R20, an amino acid peptide sequence optionally substituted with -L20A-L20B-R20;
wherein
L10A, L10B, L20A, L20B are independently a bond, a peptidyl linker, —O—, —S—,
—C(O)—, —C(O)O—, —C(O)NH—, —S(O)2NH—, —NH—, —NHC(O)NH—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene or substituted or unsubstituted heteroarylene;
R10 and R20 are independently a reactive moiety, a diagnostic moiety, a therapeutic moiety or a detectable moiety;
wherein X1 and X12 are optionally joined together to form a cyclic peptidyl moiety; and
wherein R1 and X11 are optionally joined together to form a cyclic peptidyl moiety.

### Claim 6 (depends on 5)

The covalent complex of claim 5, wherein R20 is a therapeutic moiety.

### Claim at position 7

-9. (canceled)

### Claim 10 (depends on 5)

The covalent complex of claim 5, wherein R20 is an anti-CD16 nanobody moiety.

### Claim 11 (depends on 5)

The covalent complex of claim 5, wherein L20A or L20B is independently a peptidyl linker.

### Claim at position 10

-13. (canceled)

### Claim 14 (depends on 5)

The covalent complex of claim 5, wherein said thiol side chain amino acid at position X6 is Cys.

### Claim 15 (depends on 14)

The covalent complex of claim 14, wherein X8 is Arg.

### Claim 16 (depends on 15)

The covalent complex of claim 15, wherein X0 is null.

### Claim 17

(canceled)

### Claim 18 (depends on 16)

The covalent complex of claim 16, wherein X1 and X12 are Ser.

### Claim 19 (depends on 18)

The covalent complex of claim 18, wherein X5 is β,β′-diphenyl-Ala.

### Claim at position 17

-21. (canceled)

### Claim 22 (depends on 19)

The covalent complex of onc claim 19, wherein R2 is -Gly-Gly-Lys or -Gly-Gly-Ser-Lys.

### Claim at position 19

-24. (canceled)

### Claim 25 (depends on 1)

The covalent complex of claim 1, wherein said peptide compound comprises the sequence of SEQ ID NO:1.

### Claim 26 (depends on 1)

The covalent complex of claim 1, wherein X6 is Ser.

### Claim 27 (depends on 26)

The covalent complex of claim 26, wherein X5 is β,β′-diphenyl-Ala.

### Claim 28 (depends on 27)

The covalent complex of claim 27, wherein said thiol side chain amino acid at position X8 is a substituted arginine.

### Claim 29

(canceled)

### Claim 30 (depends on 28)

The covalent complex of claim 28, wherein X0 and X1 are null.

### Claim 31 (depends on 30)

The covalent complex of claim 30, wherein X11 is lysine.

### Claim at position 27

-35. (canceled)

### Claim 36 (depends on 1)

The covalent complex of claim 1, wherein said peptide compound comprises the sequence of SEQ ID NO:2.

### Claim 37 (depends on 1)

The covalent complex of claim 1, wherein X6 is Ser.

### Claim 38 (depends on 37)

The covalent complex of claim 37, wherein X5 is β,β′-diphenyl-Ala.

### Claim 39 (depends on 38)

The covalent complex of claim 38, wherein X8 is Arg.

### Claim 40 (depends on 39)

The covalent complex of claim 39, wherein X12 is Ser.

### Claim at position 33

-45. (canceled)

### Claim 46 (depends on 1)

The covalent complex of claim 1, wherein said peptide compound comprises the sequence of SEQ ID NO:3.

### Claim 47 (depends on 1)

The covalent complex of claim 1, wherein said peptide compound has the formula:
R1—X0-X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-R2 (II)
wherein:
X0 is Ser or null;
X1 is Ser, Cys, Gly, β-alanine, diaminopropionic acid, β-azidoalanine, or null;
X2 is Gln or null;
X3 is Phe, Tyr, β,β′-diphenyl-Ala, His, Asp, 2-bromo-L-phenylalanine, 3-bromo-L-phenylalanine, 4-bromo-L-phenylalanine, Asn, Gln, a modified Phe, a hydratable carbonyl-containing residue, or a boronic acid-containing residue;
X4 is Asp or Asn;
X5 is Leu, β,β′-diphenyl-Ala, Phe, Trp, Tyr, a non-natural analog of phenylalanine, tryptophan, or tyrosine, a hydratable carbonyl-containing residue, or a boronic acid-containing residue;
X6 is Ser;
X7 is the thiol side chain amino acid, Thr, or Ser;
X8 is Arg, Ala, or an amino acid comprising a side chain of the formula -L3A-L3B-R3, wherein L3A is a bond, —O—, —S—, —C(O)—, —C(O)O—, —C(O)NH—, —S(O)2NH—, —NH—, —NHC(O)NH—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene or substituted or unsubstituted heteroarylene, L3B is a chemical linker and R3 is a steric hindering chemical moiety;
X9 is the thiol side chain amino acid, Arg or Ala;
X10 is Leu, Gln, Glu, β,β′-diphenyl-Ala, Phe, Trp, Tyr; a non-natural analog of phenylalanine, tryptophan, or tyrosine, a hydratable carbonyl-containing residue, or a boronic acid-containing residue;
X11 is the thiol side chain amino acid, Gln, Lys or Arg;
X12 is Ser, Cys, Gly, 7-aminoheptanoic acid, β-alanine, diaminopropionic acid, propargylglycine, isoaspartic acid, or null;
X13 is Gly or Ser;
X14 and X15 are independently Gly, Ser, Ala or said thiol side chain amino acid;
R1 is null, -L10A-L10B-R10, an amino acid peptide sequence optionally substituted with -L10A-L10B-R10;
R2 is null, -L20A-L20B-R20, an amino acid peptide sequence optionally substituted with -L20A-L20B-R20;
wherein
L10A, L10B, L20A, L20B are independently a bond, a peptidyl linker, —O—, —S—,
—C(O)—, —C(O)O—, —C(O)NH—, —S(O)2NH—, —NH—, —NHC(O)NH—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene or substituted or unsubstituted heteroarylene;
R10 and R20 are independently a reactive moiety, a diagnostic moiety, a therapeutic moiety or a detectable moiety; and
wherein X1 and X12 are optionally joined together to form a cyclic peptidyl moiety.

### Claim 48 (depends on 47)

The covalent complex of claim 47, wherein R20 is a therapeutic moiety.

### Claim at position 37

-51. (canceled)

### Claim 52 (depends on 47)

The covalent complex of claim 47, wherein R20 is an anti-CD16 nanobody moiety.

### Claim 53 (depends on 47)

The covalent complex of claim 47, wherein L20A or L20B is independently a peptidyl linker.

### Claim at position 40

-55. (canceled)

### Claim 56 (depends on 47)

The covalent complex of claim 47, wherein X15 is said thiol side chain amino acid.

### Claim at position 42

-59. (canceled)

### Claim 60 (depends on 47)

The covalent complex of claim 47, wherein said peptide compound comprises the sequence of SEQ ID NO:3.

### Claim at position 44

-74. (canceled)

### Claim 75

A peptide compound of formula:
R1—X0-X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-R2 (I)
wherein:
X0 is Ser or null;
X1 is Ser, Cys, Gly, β-alanine, diaminopropionic acid, β-azidoalanine, or null;
X2 is Gln or null;
X3 is Phe, Tyr, β,β′-diphenyl-Ala, His, Asp, 2-bromo-L-phenylalanine, 3-bromo-L-phenylalanine, 4-bromo-L-phenylalanine, Asn, Gln, a modified Phe, a hydratable carbonyl-containing residue, or a boronic acid-containing residue;
X4 is Asp or Asn;
X5 is Leu, β,β′-diphenyl-Ala, Phe, Trp, Tyr, a non-natural analog of phenylalanine, tryptophan, or tyrosine, a hydratable carbonyl-containing residue, or a boronic acid-containing residue;
X6 is Cys or Ser;
X7 is Cys, Thr, or Ser;
X8 is protected Arg, Arg, Ala, or an amino acid comprising a side chain of the formula -L3A-L3B-R3, wherein L3A is a bond, —O—, —S—, —C(O)—, —C(O)O—, —C(O)NH—, —S(O)2NH—, —NH—, —NHC(O)NH—,substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene or substituted or unsubstituted heteroarylene, L3B is a chemical linker and R3 is a steric hindering chemical moiety;
X9 is Cys, Arg or Ala;
X10 is Leu, Gln, Glu, β,β′-diphenyl-Ala, Phe, Trp, Tyr; a non-natural analog of phenylalanine, tryptophan, or tyrosine, a hydratable carbonyl-containing residue, or a boronic acid-containing residue;
X11 is Cys, Gln, Lys or Arg;
X12 is Ser, Cys, Gly, 7-aminoheptanoic acid, β-alanine, diaminopropionic acid, propargylglycine, isoaspartic acid, or null;
R1 is null, -L10A-L10B-R10, amino acid peptide sequence optionally substituted with -L10A-L10B-R10;
R2 is null, -L20A-L20B-R20, an amino acid peptide sequence optionally substituted with -L20A-L20B-R20;
wherein
L10A, L10B, R20A, L20B are independently a bond, a peptidyl linker, —O—, —S—,
—C(O)—, —C(O)O—, —C(O)NH—, —S(O)2NH—, —NH—, —NHC(O)NH—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene or substituted or unsubstituted heteroarylene;
R10 and R20 are independently a reactive moiety, a diagnostic moiety, a therapeutic moiety or a detectable moiety;
wherein X1 and X12 are optionally joined together to form a cyclic peptidyl moiety; and
wherein R1 and X11 are optionally joined together to form a cyclic peptidyl moiety.

### Claim 76 (depends on 75)

The compound of claim 75, wherein R20 is a therapeutic moiety.

### Claim at position 47

-83. (canceled)

### Claim 84 (depends on 75)

The compound of claim 75, wherein X6 is Cys.

### Claim 85 (depends on 75)

The compound of claim 75, wherein X8 is Arg.

### Claim at position 50

-87. (canceled)

### Claim 88 (depends on 75)

The compound of claim 75, wherein X1 and X12 are Ser.

### Claim 89 (depends on 75)

The compound of claim 75, wherein X5 is β,β′-diphenyl-Ala.

### Claim at position 53

-93. (canceled)

### Claim 94 (depends on 75)

The compound of claim 75, wherein said peptide compound is a linear peptide compound. wherein said peptide compound comprises the sequence of SEQ ID NO:1.

### Claim 95 (depends on 75)

The compound of claim 75, wherein X6 is Ser.

### Claim 96 (depends on 76)

The compound of claim 76, wherein X5 is β,β′-diphenyl-Ala.

### Claim 97 (depends on 96)

The compound of claim 96, wherein X8 is Arg.

### Claim 98 (depends on 97)

The compound of any one of claim 97, wherein X12 is Ser.

### Claim at position 59

-102. (canceled)

### Claim 103 (depends on 75)

The compound of claim 75, wherein said peptide compound comprises the sequence of SEQ ID NO:3.

### Claim 104

A peptide compound of formula:
R1—X0-X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-R2 (II)
wherein:
X0 is Ser or null;
X1 is Ser, Cys, Gly, β-alanine, diaminopropionic acid, β-azidoalanine, or null;
X2 is Gln or null;
X3 is Phe, Tyr, β,β′-diphenyl-Ala, His, Asp, 2-bromo-L-phenylalanine, 3-bromo-L-phenylalanine, 4-bromo-L-phenylalanine, Asn, Gln, a modified Phe, a hydratable carbonyl-containing residue, or a boronic acid-containing residue;
X4 is Asp or Asn;
X5 is Leu, β,β′-diphenyl-Ala, Phe, Trp, Tyr, a non-natural analog of phenylalanine, tryptophan, or tyrosine, a hydratable carbonyl-containing residue, or a boronic acid-containing residue;
X6 is Ser;
X7 is Cys, Thr, or Ser;
X8 is Arg, Ala, or an amino acid comprising a side chain of the formula -L3A-L3B-R3, wherein L3A is a bond, —O—, —S—, —C(O)—, —C(O)O—, —C(O)NH—, —S(O)2NH—, —NH—, —NHC(O)NH—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene or substituted or unsubstituted heteroarylene, L3B is a chemical linker and R3 is a steric hindering chemical moiety;
X9 is Cys, Arg or Ala;
X10 is Leu, Gln, Glu, β,β′-diphenyl-Ala, Phe, Trp, Tyr; a non-natural analog of phenylalanine, tryptophan, or tyrosine, a hydratable carbonyl-containing residue, or a boronic acid-containing residue;
X11 is Cys, Gln, Lys or Arg;
X12 is Ser, Cys, Gly, 7-aminoheptanoic acid, β-alanine, diaminopropionic acid, propargylglycine, isoaspartic acid, or null;
X13 is Gly or Ser;
X14 and X15 are independently Gly, Ser, Ala, or Cys;
R1 is null, -L10A-L10B-R10, an amino acid peptide sequence optionally substituted with -L10A-L10B-R10;
R2 is null, -L20A-L20B-R20, an amino acid peptide sequence optionally substituted with -L20A-L20B-R20;
wherein
L10A, L10B, L20A, L20B are independently a bond, a peptidyl linker, —O—, —S—,
—C(O)—, —C(O)O—, —C(O)NH—, —S(O)2NH—, —NH—, —NHC(O)NH—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene or substituted or unsubstituted heteroarylene;
R10 and R20 are independently a reactive moiety, a diagnostic moiety, a therapeutic moiety or a detectable moiety; and
wherein X1 and X12 are optionally joined together to form a cyclic peptidyl moiety.

### Claim at position 62

-116. (canceled)

### Claim 117 (depends on 104)

The compound of of claim 104, wherein said peptide compound comprises the sequence of SEQ ID NO:3.

### Claim 118

An antigen binding domain comprising:
(1) a central hole enclosed by the heavy chain variable (VH) region, the light chain variable (VL) region, the heavy chain constant (CH1) region and the light chain constant (CL) region of said antigen binding domain between a first cavity and a second cavity; and
(2) a non-CDR peptide binding region comprising:
(a) said first cavity lined by a first set of amino acid residues of the VH, VL, CH1, and CL regions of said antigen binding domain, wherein said first set of amino acid residues comprises a cysteine at a position corresponding to Kabat position 102, 142 or 143 of said VL region;
(b) said second cavity lined by a second set of amino acid residues of the VH, VL, CH1, and CL regions of said antigen binding domain, wherein said second set of amino acid residues comprises a cysteine at a position corresponding to Kabat position 208 or 158 of said VH region; or
(c) a hole region enclosing said hole between said first cavity and said second cavity, said hole region lined by a third set of amino acid residues of the VH, VL, CH1, and CL regions of said antigen binding domain, wherein said third set of amino acid residues comprises a cysteine at a position corresponding to Kabat position 174 or 175 of said VH region.

### Claim at position 65

-128. (canceled)
